Does all this hoopla mean we have no chance for a buyout by Roche, Pfizer, et al, within the next twelve months?

Roche? Pfizer was supposed to be the potential purchaser???

What happens when the 45-day extension expires? Assuming the contract is either renewed or dropped, will the announcement be made on or about day 46 or delayed? Anyone have ideas? Is the magic date August 13, 2010 or do only weekdays count?

My copy says, "Risk not thy whole wad.

The following paragraph is from Men's Health magazine.

"By age 40, up to 80% of U.S. adults are infected with cytomegalovirus (CMV), a member of the herpes virus family that rarely causes symptoms. Researchers at Beth Israel Deaconess Medical Center found that mice infected with the virus had higher blood pressure than CMV-free ones."

My question: Could Bavi, as an antiviral, be effective in lowering hypertension? Wouldn't cost much to test more mice. Just look at the potential for a blood pressure control medicine with few, if any, side effects. Bavi has already been proven safe.

I agree $5.00 is too low but my point is once we get the PPS above $5.00 we open up a whole new area of media coverage and institutional investors. Don't just sit there, buy some PPHM. I'd do it but I'm tapped-out with what I have.

To heck w/$4! I'm a $5 instead of $4 man (also $5 for $4 when loaning money.) Why do you keep wasting our time with $4?

Heck with $4, let's get it over $5! LOL

When does the PPS surpass $5? That is when the fireworks begin.

We will open up a whole new class of media coverage and potential investors when we get the pps above $5.00.

And just you wait until the pps exceeds $5/share!!!

Why isn't PPHM listed in this.

http://seekingalpha.com/article/197683-7-companies-in-the-race-to-find-cures-for-cancer?source=article_sb_popular

What is the 200-week EMA, $3.70? We could take this out tomorrow.

We need to break 200-day moving average at about $3.40. Don't just sit there, buy some shares!

The price charts almost an overlay.

A stock must be above $5/share to attract the needed following. That is why I was in favor of a 1 for 10 reverse split instead of the 1 for five. If and when we get the pps above $5/share we will have analyst, media and investor coverage.

Isn't the 200 day moving average about $3.50? Looks like we could break through!

You should ask them again. The poison pill language specifically provides for adjustments and according to that language the number changed from $11 to $55/share. Additionally, several posts on this board have covered this topic. Check the SEC filings if you want to read the language yourself.

Whatever happened to the use of Bavi as a diagnostic tool in "lighting up" tumors?

When can we expect a comprehensive update of ongoing clinical trials?

Biotech stocks are in a recovery mode and poised for a Q4 rally extending to early January, according to Raynoreport.com's chief biotech contributor Raygent Associates.

Raygent notes that the year-end rally has been a trend in the past few years (’05,’06 and ’07 trends), though it was certainly disrupted by the recent financial crisis of ‘08/09. The IBB tracking ETF looks to be basing at levels of 75-79, so a rally would take this popular ETF beyond 80, seeking the September highs of 85.

Partnerships and good clinical news have given support to biotech stocks lately and the sentiment has improved especially with biotech financing.

Stocks with interesting potential include Cephalon (CEPH), Cubist (CBST), Supergen (SUPG) and ViroPharma (VPHM).

Additional smaller cap positions that could be added are: Alnylam (ALNY), a core play in RNA interference therapeutics for infectious disease and cancer; Idera (IDRA), a core play in immune response therapeutics through targeted Toll Receptors for infectious and inflammatory disease; and SeraCare (SRLS), a biological products and services Company in a turnaround mode with revenues growing to the $50 million range and a profitable quarter

Sigh, Why is PPHM never mentioned in these articles?

What happened to the use of Bavi as a diagnostic tool in identifing tumors?

Don't worry, be happy!

Moby, one or more BP are well aware of SK, Dr. Thorpe & PPHM's pipeline. They are enthusiastic and waiting on final Phase II results.

You will deliver and help dispose of JWB if the PPHM exceeds $20/share by year’s end. While in Saint Thomas, where ice is at a premium, I kept scotch in the freezer and continue this practice on the mainland. Please be sure you keep the JWB in a freezer until we meet to devour. Had a similar bet with the prize being a bottle of Usquebaugh. The sorry loser drank his without ice so he would get more. I know you wouldn't do that!

This Board sure gets quiet when the pps goes up???

Since a 1 for 10 split to raise the PPS above $5 was preferred for the benefit of attracting additional news coverage, institution and other large investors, why would PPHM limit the R/S to a measly 1 for 5? Perhaps the explanation is PPHM is aware many shareholders are strongly opposed to any R/S but to protect against delisting, it was absolutely necessary to raise the PPS above $1 before the deadline. To keep all options open, PPHM must not be delisted. Why then would PPHM not be interested in the 1 for 10 split to attract additional news coverage, institution and other large investors? The reason could be PPHM has deals pending with one or more Big Pharma, awaiting the outcome of clinical trials, etc., and have reasons for structuring the R/S that are not now public knowledge. This may also explain retention of a large number of unissued shares that can be swapped or otherwise traded in a partnership, merger or acquisition. During personal discussion with an employee of a Big Pharma heavily involved in HIV research, the employee advised that many of his own company's experimental products failed during phase III trials and most Big Pharma, including his, are very skittish until favorable results have been documented. Don’t worry, be happy! PPHM management is doing a fantastic job of sailing this company to the promised land. Moby, get ready to deliver that JWB!

Moby, sounds Like A Great Deal To Me!

Doesn't your argument assume those shares are issued for no value to the company? Why does capitalization equal share price times shares outstanding? The answer is that shares held in the company's treasury are an asset of the company and when issued the company receives value. Secondary offerings can be dilutive if the company accepts less value than the PPS at the time of issue, which some companies do to stay afloat. This will not be the case with PPHM. One or more Big Pharma are well aware of SK and PPHM's pipeline. I will not be suprised if PPHM's shareholders receive a handsome partnership, merger or acquisition offer before the end of the year. I wished for a 1 for 10 reverse split but you know what happens when you hold out one hand to fill with wishes and deficate in the other.

If and when shares that are not outstanding as of the r/S are sold to the public, acquired by a BP as part of a partnership, merger or acquisition, don't we shareholders receive our proportionate share of the proceeds?

Wrong, The reverse split, which was approved by Peregrine shareholders in October 2008, will reduce the number of shares of outstanding common stock from approximately 237 million as of the filing of the Company's most recent Quarterly Report on Form 10-Q to approximately 47.4 million.

Wrong Moby, The Agreement specifically provides for splits.

AMEN!

Jess:

We announced grants and contracts recently but were not included in this extensive list of biotechs receiving same. Any ideas why?

1)Peregrine marches to a different drummer?

No, PPHM is in the same business as those companies listed.

2) Tustin is waiting for the RS to release any of this information so the post split price doesn't decline too much?

No, PPHM released the info about the grants and contracts,

3)Peregrine isn't as well known as some would have us beleive? Recall all the PS abstracts which some think are related to Bavi and Peregrine yet neither are ever mentioned.

Bingo! Peregrine has no control over which companies are covered by the media and companies trading below $1 do not get the same coverage as those trading above $1. However, BP are mostly very aware of PPHM’s pipeline and are awaiting results of the ongoing clinical trials.

4)I'm sure there are many more reasons.

Maybe, but our “too low” price prevents CNBC, et al, from covering PPHM and prohibits many large and institutional investors from following PPHM. This is why we must get the price up, one way or another.

It is disheartening that PPHM is never mentioned in articles such as the following.

http://seekingalpha.com/article/164667-capital-markets-open-up-to-biotechs?source=email

We announced grants and contracts recently but were not included in this extensive list of biotechs receiving same. Any ideas why?

Up, you have to admit it is extremely discouraging that these articles do not mention PPHM and Thorpe, even though the Company enjoys patents covering this very subject.

Big Pharma know SK well and are favorably impressed with PPHM's pipeline. They are waiting on final results of the various clinical trials to lower their perception of risk. Meanwhile, back at the ranch, PPHM is posturing to proceed alone with phase III clinical trials, just in case they don't like the deals BP offers. You can be assured the chips are flying!

geocappy1, it is amazing that boards such as this do not become synergistic collections of individuals, all working toward a common purpose but it never happens. If every board member had a common purpose, there would be no acrimony. Each member would bring all he could to the table and take away all he could learn. Different members with different backgrounds may have different perspectives but since each member has the same goal, being invested in a company they think will make them a profit and have a little fun in the process, each tries to help the others. If a board member wrongly perceives a situation, etc. other board members may cordially explain the misperception. No member would intentionally mislead another board member.

Can anyone explain what happens to PPHM’s poison pill in the event of a 1 for 10 reverse split?

Assuming: 1) one or more BP is familiar with SK and PPHM but are waiting on final results from ongoing and pending Phase II clinical trials before making a commitment; and 2) PPHM, because of the successful expansion of Avid, has decided to “go it alone” with Phase III clinical trials.

A situation could exist whereby PPHM would need the protection of the poison pill. If the PP was removed by the R/S could the BP accomplish a hostile takeover to the detriment of shareholders? If the PP remains, PPHM's decision to "go it alone" puts the company in a much stronger bargaining position.

Just speculation on my part.

$75 to $100 million plus tangible equipment salvage value, being a approximately a 20% internal rate of return.

Hawking a company such as PPHM below $5 is pushing on a string. Most serious/institutional investors will not even look at a stock below $5 and many media outlets will not report on “penny stocks.” The reverse split should have occurred a year ago. Once PPHM gets above $5.00 the company will be able to enjoy the respect it deserves. Yes, even if I knew the stock would drop to $5 after a 1 for 10 reverse split, I would vote for the split because this past year of outstanding accomplishment proves we shareholders cannot prosper as a $0.75 stock with 237.1 million shares.

What about a writing campaign to possible acquisition, merger, partner BPs. While PPHM management may be doing all possible to find partners, etc. what would it hurt for shareholders to communicate with BP personnel to see if they are aware of what PPHM has to offer? One could forward the clinical trial status chart and patent inventory from PPHM’s website to BPs with sparse pipelines and expiring patents. Sometimes successful partnering, etc. depends on alerting the right person at the right time.